What diseases does Upatinib mainly treat? Description of indications and applicable groups

Upadacitinib (Upadacitinib) is a selective Janus kinase 1 (JAK1) inhibitor. It is a new targeted small molecule drug that has attracted worldwide attention in recent years and is widely used in the treatment of a variety of chronic autoimmune diseases. The drug was originally developed by AbbVie and was first approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to or are intolerant to one or more traditional synthetic antirheumatic drugs (such as methotrexate). By targeting JAK1, upadatinib can effectively block the cytokine signaling pathway, thereby reducing the inflammatory response and relieving joint swelling, pain and dysfunction.

In addition to rheumatoid arthritis, upadacitinib is also approved for the treatment of autoimmune-related diseases such as moderately to severely active Crohn's disease, ulcerative colitis, atopic dermatitis (eczema), and psoriatic arthritis (PsA). Especially in the field of atopic dermatitis, upadatinib has become another key treatment option after topical hormones and biological agents due to its oral administration method and rapid onset of action. For patients with Crohn's disease, upadatinib is considered to have significant efficacy in controlling intestinal inflammation and improving symptoms, especially for patients who are refractory to traditional immunomodulators or TNF-α inhibitors.

In terms of the applicable population, upadatinib is usually suitable for the adult population, but in recent years its safety and effectiveness in adolescents have been gradually verified. For example, its scope of application has been gradually expanded in patients with severe atopic dermatitis over the age of 12. Overall, upadatinib is a targeted drug suitable for long-term chronic management and for patients who are ineffective or intolerant to traditional treatments. Because of its high targeting and predictable adverse reaction spectrum, it is gradually being widely used in clinical practice.

Reference materials:https://www.rinvoq.com/